President - Daniel G. Smith, Ph.D.
Dr. Smith holds a dual role as the president of DELSIA and senior director of discovery research at Autism Speaks. He oversees DELSIA’s strategy and operations and a research portfolio focused on diagnostics, biomarkers and therapeutic interventions for autism. Daniel joined Autism Speaks in 2012 after leading discovery research laboratories in the pharmaceutical sector, most recently as senior principal scientist and laboratory head in the Neuroscience Research Unit at Pfizer.
Dr. Clayton holds a dual role as DELSIA’s treasurer and Autism Speaks’ senior director of strategic funding and grants administration. As part of his Autism Speaks duties, Dr. Clayton oversees the grants program and review process as well as the pre- and post-doctoral fellowship portfolios. Before joining Autism Speaks, Dr. Clayton was a Scientific Review Officer at the National Institutes of Health. Prior to NIH, Dr. Clayton conducted cognitive neuroscience research at the University of Pennsylvania.
Board of Managers
Chairman of the Board of Managers- Robert H. Ring, Ph.D.
Dr. Ring holds a dual role as DELSIA’s chairman of the board of managers and Autism Speaks’ chief science officer, providing overall leadership for Autism Speaks science programs and initiatives. Prior to joining Autism Speaks in 2011, Dr. Ring served as senior director and head of the Autism Research Unit at Pfizer Worldwide Research and Development, in Groton, Conn. Prior to Pfizer, Dr. Ring gained a decade experience in psychiatric drug discovery and development at Wyeth Research, in Princeton, N.J. Dr. Ring holds adjunct faculty appointments in psychiatry at Mount Sinai School of Medicine and in pharmacology and physiology at Drexel University College of Medicine.
Curtis Arledge is vice chairman of BNY Mellon and chief executive officer of BNY Mellon Asset Management. Additionally, Curtis is responsible for BNY Mellon Wealth Management, and is a member of BNY Mellon's Executive Committee, which is the senior-most governing body of the corporation. Prior to joining BNY Mellon in November 2010, Curtis was the chief investment officer for fundamental fixed income portfolios at BlackRock, Inc. He joined BlackRock from Wachovia Corporation, where he was the global head of the fixed income division within the bank's corporate and investment banking group. He spent 12 years of his career at Wachovia, and had oversight for various business lines in the U.S., Europe and Asia, including leveraged finance, investment grade, global rates, structured products, corporate loan and commercial real estate portfolios, and financial institutions investment banking. He and his wife, Diane, have a son on the autism spectrum.
Gary W. Goldstein, M.D.
Dr. Goldstein is the president and chief executive officer of Kennedy Krieger Institute, in Baltimore, Md. He is also a professor of neurology and pediatrics at Johns Hopkins University School of Medicine and a professor of environmental health sciences at Johns Hopkins University School of Hygiene and Public Health. Dr. Goldstein is also a member of the Autism Speaks Board of Directors.
Adrian M. Jones
Mr. Jones is a managing director at Goldman Sachs, in New York, in the company's principal investment area. He joined Goldman Sachs in 1994 as an associate of the Investment Banking Division. He also served in the company's communications and media department on mobility assignments in equity capital markets and in the executive office of Goldman Sachs International, in London. Mr. Jones grew up in Ireland and served as a lieutenant in the Irish Army. In 1987 and 1988, he served in the United Nations Peacekeeping Force in Southern Lebanon. Mr. Jones is a 1986 graduate of University College in Galway and earned his MBA from Harvard in 1994. He is the father of a child with autism. Mr. Jones is also a member of the Autism Speaks Board of Directors.